The role of free immunoglobulin light chains in serum from SLE patients with or without renal involvement
  
View Full Text  View/Add Comment  Download reader
DOI:
KeyWord:free immunoglobulin light chains  SLE  lupus nephritis
                             
AuthorInstitution
Adriana Aguirre Telio Central Laboratory, Molecular Biology Area, Instituto Nacional de Ciencias Médicasy Nutricion Salvador Zubirán, Mexico City 14000, Mexico
Citlaly López Orozco Transplant Department, Instituto Nacional de Ciencias Medicasy Nutricion Salvador Zubiran, Mexico City 14000,Mexico.
Susana Maricela Hernández Do?o Transplant Department, Instituto Nacional de Ciencias Medicasy Nutricion Salvador Zubiran, Mexico City 14000,Mexico.
Daniela Ruiz Gómez Fundacion Clinica Medica Sur, Mexico City 14000,Mexico
Víctor Hugo Tovar Méndez Instituto Nacional de Ciencias Médicasy Nutricion Salvador Zubiran, Mexico City 14000,Mexico
María Fernanda García Gutiérrez Instituto Nacional de Ciencias Médicasy Nutricion Salvador Zubiran, Mexico City 14000,Mexico
Miriam Santiago Ortíz Universidad Anahuac, Facultad de Ciencias de la Salud, Huixquilucan, State of Mexico 14000, Mexico
Marcos Meneses Mayo Universidad Anahuac, Facultad de Ciencias de la Salud, Huixquilucan, State of Mexico 14000, Mexico
Antonio Villa-Romero Research Department. Universidad Panamericana, Mexico City 14000, Mexico
Julio Granados Transplant Department, Instituto Nacional de Ciencias Medicasy Nutricion Salvador Zubiran,Mexico City 14000,Mexico
Hits: 17
Download times: 17
Abstract:
      Systemic lupus erythematosus (SLE) is a systemic autoimmune disease. Lupus nephritis (LN) affects 30% to 60% of adult Mexican patients. This study aimed to determine whether immunoglobulin free light chains (FLCs) constitute a biological marker for LN. FLCs have been previously studied as disease activity biomarkers, but patients with kidney damage are frequently excluded. A total of 75 consecutive SLE patients were recruited from a third-level hospital in Mexico City. Thirty-eight patients were diagnosed with LN, and the remaining 37 patients without kidney failure were included as a control group. FLCs concentration was measured by nephelometry. The results showed that SLE patients with high FLCs concentration had a higher rate of kidney failure and that the probability of renal failure increased by 2.4% for each mg/dL of κ FLCs, and 1.7% for each mg/dL of λ FLCs. This study suggests that high FLCs concentration is associated with LN, and therefore may be considered as a possible biomarker for SLE activity.
Close